Tanım

Biological therapy, also called immunotherapy, biological response modifier therapy, or biotherapy, uses the body’s immune system to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Biological therapy for cancer is used in the treatment of many types of cancer to prevent or slow tumor growth and to prevent the spread of cancer. The global cancer biological therapy market is set to grow by US$ 37.45 sırasında milyar 2021-2027, yıllık bileşik büyüme oranında büyüyor (CAGR) ile ilgili 6.8% tahmin dönemi boyunca, veri ve analiz şirketi StratejiHelix'e göre. Rising geriatric population, rising incidence of cancer, favorable government regulations and market initiatives, increasing research & development activities are expected to boost the market growth in the coming years.

Rapor, döneme ilişkin güncel pazar büyüklüğü verilerini sağlar 2017-2020 ve tahmin 2027 covering key market aspects like sales value for cancer biological therapy. The global cancer biological therapy market is segmented on the basis of product, region. Ürüne göre, it is categorized into monoclonal antibodies, vaccines, and CAR T-cell therapy. The monoclonal antibodies segment held the largest market share in 2020. By region, the cancer biological therapy market is divided into North America, Asya Pasifik, Avrupa, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals Inc., Merck KGaA, Novartis International AG, Pfizer Inc..

Rapor, bu sektörde faaliyet gösteren şirket ve kuruluşlar için paha biçilmez bir kaynaktır. It provides a cohesive picture of the cancer biological therapy market to help drive informed decision making for industry executives, kural koyucular, akademik, ve analistler.

Rapor Kapsamı

Ürün: monoclonal antibodies, vaccines, and CAR T-cell therapy
Bölge: Kuzey Amerika, Asya Pasifik, Avrupa, and Rest of the World (ROW)
Düşünülen Yıllar: bu rapor dönemi kapsamaktadır 2017 ile 2027

Paydaşlar için Temel Faydalar

Get a comprehensive picture of the global cancer biological therapy market
Büyüme sektörlerini ve yatırım eğilimlerini belirleyin
Understand what the future of the global cancer biological therapy market looks like
Rekabet ortamını ve fırsat penceresini belirleyin

İçindekiler

1. Pazar Tanımı
2. Araştırma Metodolojisi
3. Piyasa verileri & Görünüm
3.1 Market değeri
3.2 Piyasa Değeri Tahmini
4. Cancer Biological Therapy Market by Product
4.1 Monoclonal Antibodies
4.2 Vaccines
4.3 Car T-Cell Therapy
5. Cancer Biological Therapy Market by Region
5.1 Kuzey Amerika
5.2 Asya Pasifik
5.3 Avrupa
5.4 Rest Of The World (Row)
6. Şirket profilleri
6.1 Amgen Inc.
6.2 AstraZeneca plc
6.3 Bristol-Myers Squibb Company (BMS)
6.4 Eli Lilly and Company
6.5 F. Hoffmann-La Roche AG
6.6 Genmab A/S
6.7 Gilead Sciences, A.Ş..
6.8 GlaxoSmithKline plc (GSK)
6.9 Janssen Pharmaceuticals, A.Ş..
6.10 Merck KGaA
6.11 Novartis International AG
6.12 Pfizer Inc.
7. Ek
7.1 StratejiHelix Hakkında
7.2 Sorumluluk reddi beyanı